Drug intelligence / Profile preview

SK1808

Development stage: Unknown
Lead developer: Shenzhen Sciencare Pharmaceutical
Modality: Small Molecules
Administration: Implant

Overview

SK1808 is a long-acting naltrexone hydrochloride implant developed by Shenzhen Sciencare Pharmaceutical for the treatment of opioid use disorder (OUD). Naltrexone is a potent opioid antagonist that competitively binds to mu-opioid receptors in the central nervous system, effectively blocking the euphoric and physiological effects of exogenous opioids. This specific formulation is designed as a long-term drug delivery system to provide sustained therapeutic levels of naltrexone over an extended period, aiming to improve patient compliance and prevent relapse in individuals who have undergone detoxification. SK1808 is currently in Phase 1 clinical development in China.

Brand names: Depotrex
Other names: naltrexone hydrochloride implant

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on SK1808.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK1808.

Explore the full profile